Streetbeat News

Regulatory

FTNT

Fortinet, Inc. (NASDAQ:FTNT) has released a report warning of cyberthreats targeting the 2024 U.S. presidential election, including phishing scams, AI impersonations, and ransomware attacks. The report highlights increased cyber espionage activities from state-sponsored adversaries like China, Russia, and Iran. Fortinet emphasizes the importance of good cyber hygiene to protect against these threats.

Portfolio Pulse from Erica Kollmann

October 15, 2024 | 9:28 pm

DRCT

Direct Digital Holdings has reported its filings for the full-year 2023, Q1 2024, and Q2 2024. The company is awaiting a formal compliance determination from Nasdaq regarding its listing compliance.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 9:08 pm

BDRX

Biodexa Pharmaceuticals (NASDAQ:BDRX) shares surged after-hours following an extension granted by the Nasdaq Hearings Panel to meet the $1 minimum bid price requirement. The company has until Oct. 31 to comply, with shares trading at $9. A recent ADR ratio change acted as a 1-for-20 reverse stock split.

Portfolio Pulse from Adam Eckert

October 15, 2024 | 9:02 pm

NVCR

Novocure announced that the FDA has approved its product, Optune Lua, for the treatment of metastatic non-small cell lung cancer. This approval could potentially enhance Novocure's market position and revenue prospects.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:44 pm

NVCR

NovoCure's shares rose following FDA approval of Optune Lua for treating metastatic non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:39 pm

URGN

UroGen Pharma's shares rose following the FDA's acceptance of its new drug application for UGN-102.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:35 pm

CTCX

Carmell Corp has filed a Form RW with the SEC, indicating that it will not pursue a previously planned securities offering. The company confirmed that no securities have been issued or sold, and the registration statement has not been declared effective.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:34 pm

BDRX

Biodexa Pharmaceuticals shares rose after successfully appealing Nasdaq's delisting decision, gaining more time to comply with listing rules.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:33 pm

URGN

UroGen Pharma Ltd. announced that the FDA has accepted its New Drug Application for UGN-102, a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. The PDUFA goal date is set for June 13, 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:32 pm

BDRX

Biodexa Pharmaceuticals has been granted an extension by the Nasdaq Hearings Panel to meet the $1 minimum bid price requirement. This extension provides the company additional time to comply with Nasdaq's listing rules.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:31 pm